CY1123173T1 - Παραγωγα 4-αμινο-2-(1η-πυραζολο[3,4-β]πυριδιν-3-υλ)-6-οξο-6,7-διϋδρο-5η-πυρρολο[2,3-d]πυριμιδινης και τα αντιστοιχα παραγωγα (1η-ινδαζολ-3-υλιου) ως διαμορφωτες cgmp για αγωγη καρδιαγγειακων παθησεων - Google Patents
Παραγωγα 4-αμινο-2-(1η-πυραζολο[3,4-β]πυριδιν-3-υλ)-6-οξο-6,7-διϋδρο-5η-πυρρολο[2,3-d]πυριμιδινης και τα αντιστοιχα παραγωγα (1η-ινδαζολ-3-υλιου) ως διαμορφωτες cgmp για αγωγη καρδιαγγειακων παθησεωνInfo
- Publication number
- CY1123173T1 CY1123173T1 CY20201100547T CY201100547T CY1123173T1 CY 1123173 T1 CY1123173 T1 CY 1123173T1 CY 20201100547 T CY20201100547 T CY 20201100547T CY 201100547 T CY201100547 T CY 201100547T CY 1123173 T1 CY1123173 T1 CY 1123173T1
- Authority
- CY
- Cyprus
- Prior art keywords
- disease
- pharmaceutically acceptable
- acceptable salts
- treatment
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Η εφεύρεση παρέχει ενώσεις του Χημικού Τύπου (Ι) ή φαρμακευτικώς αποδεκτά άλατα εξ αυτών, όπου τα Χ, Υ, Ζ, R1, R2, R4, Ra, και οι κάτω δείκτες m, p, και q είναι όπως περιγράφονται εις το παρόν. Οι ενώσεις ή τα φαρμακευτικώς αποδεκτά άλατα αυτών μπορούν να διαμορφώσουν την παραγωγή της μονοφωσφορικής κυκλικής γουανοσίνης ("cGMP") του σώματος, και είναι γενικώς κατάλληλες για την θεραπεία και προφύλαξη παθήσεων οι οποίες συσχετίζονται με μία διαταραγμένη ισορροπία cGMP, όπως είναι καρδιαγγειακή πάθηση, η ενδοθηλιακή δυσλειτουργία, η διαστολική δυσλειτουργία, η αθηροσκλήρυνση, η υπέρταση, η ανεπάρκεια της καρδιάς, η πνευμονική υπέρταση, (ομάδες Π.Ο.Υ. Ι, II, III, IV), η στηθάγχη, η θρόμβωση, η επαναστένωση, η μυοκαρδιακή έμφραξη, το εγκεφαλικό επεισόδιο, η καρδιακή ανεπάρκεια, η ίνωση, η πνευμονική υπερτονία, η στυτική δυσλειτουργία, το άσθμα, το σύνδρομο οξείας αναπνευστικής δυσχέρειας (ARDS), η χρόνια πάθηση των νεφρών, η κυστική ίνωση, η δρεπανοκυτταρική αναιμία, το σκληρόδερμα, το Σύνδρομο του Raynaud, ο διαβήτης, η διαβητική αμφιβληστροειδοπάθεια, η κίρρωση του ήπατος, η χρόνια αποφρακτική πνευμονική πάθηση (COPD), η οξεία βλάβη των πνευμόνων, η πνευμονική ίνωση ή η διάμεση πάθηση των πνευμόνων. Η εφεύρεση παρέχει επίσης φαρμακευτικές συνθέσεις οι οποίες περιλαμβάνουν ενώσεις του Χημικού Τύπου (Ι) ή φαρμακευτικώς αποδεκτά άλατα εξ αυτών. Η εφεύρεση σχετίζεται επίσης με τις ενώσεις ή τα φαρμακευτικώς αποδεκτά άλατα αυτών για χρήση στην θεραπεία και προφύλαξη των προαναφερθέντων παθήσεων και για παρασκευή φαρμακευτικών ειδών για αυτόν τον σκοπό.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2015/098251 WO2017107052A1 (en) | 2015-12-22 | 2015-12-22 | Soluble guanylate cyclase stimulators |
PCT/US2016/067654 WO2017112617A1 (en) | 2015-12-22 | 2016-12-20 | 4-amino-2-(1h-pyrazolo[3,4-b]pyridin-3-yl)-6-oxo-6,7-dihydro-5h-pyrrolo[2,3-d]pyrimidine derivatives and the respective (1h-indazol-3-yl) derivatives as cgmp modulators for treating cardiovascular diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1123173T1 true CY1123173T1 (el) | 2021-10-29 |
Family
ID=57758775
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20201100547T CY1123173T1 (el) | 2015-12-22 | 2020-06-16 | Παραγωγα 4-αμινο-2-(1η-πυραζολο[3,4-β]πυριδιν-3-υλ)-6-οξο-6,7-διϋδρο-5η-πυρρολο[2,3-d]πυριμιδινης και τα αντιστοιχα παραγωγα (1η-ινδαζολ-3-υλιου) ως διαμορφωτες cgmp για αγωγη καρδιαγγειακων παθησεων |
Country Status (39)
Country | Link |
---|---|
US (2) | US10030027B2 (el) |
EP (1) | EP3394067B1 (el) |
JP (1) | JP6454448B2 (el) |
KR (1) | KR102191312B1 (el) |
CN (1) | CN108738320B (el) |
AR (1) | AR107154A1 (el) |
AU (1) | AU2016377364B2 (el) |
BR (1) | BR112018012579B1 (el) |
CA (1) | CA3009193C (el) |
CL (1) | CL2018001671A1 (el) |
CO (1) | CO2018006300A2 (el) |
CR (1) | CR20180330A (el) |
CY (1) | CY1123173T1 (el) |
DK (1) | DK3394067T3 (el) |
DO (1) | DOP2018000153A (el) |
EA (1) | EA036445B1 (el) |
EC (1) | ECSP18054606A (el) |
ES (1) | ES2794654T3 (el) |
HK (1) | HK1255028A1 (el) |
HR (1) | HRP20200857T1 (el) |
HU (1) | HUE049941T2 (el) |
IL (1) | IL260020B (el) |
LT (1) | LT3394067T (el) |
ME (1) | ME03748B (el) |
MX (2) | MX2018007728A (el) |
MY (1) | MY194021A (el) |
NI (1) | NI201800069A (el) |
PE (1) | PE20181802A1 (el) |
PH (1) | PH12018501342A1 (el) |
PL (1) | PL3394067T3 (el) |
PT (1) | PT3394067T (el) |
RS (1) | RS60344B1 (el) |
SG (1) | SG11201805272XA (el) |
SI (1) | SI3394067T1 (el) |
SV (1) | SV2018005715A (el) |
TN (1) | TN2018000219A1 (el) |
TW (1) | TWI724079B (el) |
UA (1) | UA122264C2 (el) |
WO (2) | WO2017107052A1 (el) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3303342B1 (en) | 2015-05-27 | 2021-03-17 | Merck Sharp & Dohme Corp. | Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
US10213429B2 (en) | 2015-05-28 | 2019-02-26 | Merck Sharp & Dohme Corp. | Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
US20170107216A1 (en) | 2015-10-19 | 2017-04-20 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
AU2016358100B2 (en) | 2015-11-19 | 2021-05-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
WO2017107052A1 (en) | 2015-12-22 | 2017-06-29 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase stimulators |
DK3394033T3 (da) | 2015-12-22 | 2021-01-04 | Incyte Corp | Heterocykliske forbindelser som immunmodulatorer |
MA44860A (fr) | 2016-05-06 | 2019-03-13 | Incyte Holdings Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
WO2017197555A1 (en) | 2016-05-16 | 2017-11-23 | Merck Sharp & Dohme Corp. | Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators |
US10925876B2 (en) | 2016-05-18 | 2021-02-23 | Merck Sharp & Dohme Corp. | Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders |
US20170342060A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
BR112018076534A2 (pt) | 2016-06-20 | 2019-04-02 | Incyte Corporation | compostos heterocíclicos como imunomoduladores |
ES2930092T3 (es) | 2016-07-14 | 2022-12-07 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
EP3504198B1 (en) | 2016-08-29 | 2023-01-25 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
MY197501A (en) | 2016-12-22 | 2023-06-19 | Incyte Corp | Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers |
EP3558985B1 (en) | 2016-12-22 | 2022-09-07 | Incyte Corporation | Benzooxazole derivatives as immunomodulators |
EP3558989B1 (en) | 2016-12-22 | 2021-04-14 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
MA47120A (fr) | 2016-12-22 | 2021-04-28 | Incyte Corp | Dérivés pyridine utilisés en tant qu'immunomodulateurs |
EP3609883B1 (en) * | 2017-04-11 | 2022-06-29 | Sunshine Lake Pharma Co., Ltd. | Fluorine-substituted indazole compounds and uses thereof |
WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT |
EP3498298A1 (en) | 2017-12-15 | 2019-06-19 | Bayer AG | The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi) |
CR20200520A (es) | 2018-03-30 | 2021-03-09 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
US20210052528A1 (en) | 2018-04-30 | 2021-02-25 | Bayer Aktiengesellschaft | The use of sgc activators and sgc stimulators for the treatment of cognitive impairment |
EP3790877B1 (en) | 2018-05-11 | 2023-03-01 | Incyte Corporation | Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators |
EP3574905A1 (en) | 2018-05-30 | 2019-12-04 | Adverio Pharma GmbH | Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group |
WO2020148379A1 (en) | 2019-01-17 | 2020-07-23 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc) |
TW202115059A (zh) | 2019-08-09 | 2021-04-16 | 美商英塞特公司 | Pd—1/pd—l1抑制劑之鹽 |
TW202126652A (zh) | 2019-09-30 | 2021-07-16 | 美商英塞特公司 | 作為免疫調節劑之吡啶并[3,2—d]嘧啶化合物 |
AU2020385113A1 (en) | 2019-11-11 | 2022-05-19 | Incyte Corporation | Salts and crystalline forms of a PD-1/PD-L1 inhibitor |
WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
TW202233615A (zh) | 2020-11-06 | 2022-09-01 | 美商英塞特公司 | Pd—1/pd—l1抑制劑之結晶形式 |
CA3200844A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4845079A (en) | 1985-01-23 | 1989-07-04 | Luly Jay R | Peptidylaminodiols |
US5066643A (en) | 1985-02-19 | 1991-11-19 | Sandoz Ltd. | Fluorine and chlorine statine or statone containing peptides and method of use |
US4894437A (en) | 1985-11-15 | 1990-01-16 | The Upjohn Company | Novel renin inhibiting polypeptide analogs containing S-aryl-D- or L- or DL-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties |
US4885292A (en) | 1986-02-03 | 1989-12-05 | E. R. Squibb & Sons, Inc. | N-heterocyclic alcohol renin inhibitors |
US5089471A (en) | 1987-10-01 | 1992-02-18 | G. D. Searle & Co. | Peptidyl beta-aminoacyl aminodiol carbamates as anti-hypertensive agents |
US4980283A (en) | 1987-10-01 | 1990-12-25 | Merck & Co., Inc. | Renin-inhibitory pepstatin phenyl derivatives |
US5034512A (en) | 1987-10-22 | 1991-07-23 | Warner-Lambert Company | Branched backbone renin inhibitors |
US5063207A (en) | 1987-10-26 | 1991-11-05 | Warner-Lambert Company | Renin inhibitors, method for using them, and compositions containing them |
US5055466A (en) | 1987-11-23 | 1991-10-08 | E. R. Squibb & Sons, Inc. | N-morpholino derivatives and their use as anti-hypertensive agents |
US5036054A (en) | 1988-02-11 | 1991-07-30 | Warner-Lambert Company | Renin inhibitors containing alpha-heteroatom amino acids |
US5036053A (en) | 1988-05-27 | 1991-07-30 | Warner-Lambert Company | Diol-containing renin inhibitors |
DE3841520A1 (de) | 1988-12-09 | 1990-06-13 | Hoechst Ag | Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung |
US5106835A (en) | 1988-12-27 | 1992-04-21 | American Cyanamid Company | Renin inhibitors |
US5063208A (en) | 1989-07-26 | 1991-11-05 | Abbott Laboratories | Peptidyl aminodiol renin inhibitors |
US5098924A (en) | 1989-09-15 | 1992-03-24 | E. R. Squibb & Sons, Inc. | Diol sulfonamide and sulfinyl renin inhibitors |
US5104869A (en) | 1989-10-11 | 1992-04-14 | American Cyanamid Company | Renin inhibitors |
US5114937A (en) | 1989-11-28 | 1992-05-19 | Warner-Lambert Company | Renin inhibiting nonpeptides |
US5095119A (en) | 1990-03-08 | 1992-03-10 | American Home Products Corporation | Renin inhibitors |
US5064965A (en) | 1990-03-08 | 1991-11-12 | American Home Products Corporation | Renin inhibitors |
US5075451A (en) | 1990-03-08 | 1991-12-24 | American Home Products Corporation | Pyrrolimidazolones useful as renin inhibitors |
US5071837A (en) | 1990-11-28 | 1991-12-10 | Warner-Lambert Company | Novel renin inhibiting peptides |
US6054587A (en) | 1997-03-07 | 2000-04-25 | Metabasis Therapeutics, Inc. | Indole and azaindole inhibitors of fructose-1,6-bisphosphatase |
AU6452098A (en) | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel purine inhibitors of fructose-1,6-bisphosphatase |
DK0970095T3 (da) | 1997-03-07 | 2004-03-08 | Metabasis Therapeutics Inc | Hidtil ukendte benzimidazolinhibitorer for fructose-1,6-bisphosphase |
DE19744026A1 (de) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
DE19744027A1 (de) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Substituierte Pyrazolo[3,4-b]pyridine, ihre Herstellung und Verwendung in Arzneimitteln |
DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
AU761267C (en) | 1998-09-09 | 2007-08-09 | Metabasis Therapeutics, Inc. | Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase |
DE60128475T2 (de) | 2000-07-25 | 2008-02-07 | Merck & Co., Inc. | N-substituierte indole mit anwendung in der behandlung von diabetes |
WO2002060388A2 (en) | 2001-01-30 | 2002-08-08 | Merck & Co., Inc. | Acyl sulfamides for treatment of obesity, diabetes and lipid disorders |
DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
AR040241A1 (es) | 2002-06-10 | 2005-03-23 | Merck & Co Inc | Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia |
AU2003260085B2 (en) | 2002-08-29 | 2008-09-11 | Merck & Co., Inc. | Indoles having anti-diabetic activity |
CA2495943C (en) | 2002-08-29 | 2009-07-21 | Merck & Co., Inc. | Indoles having anti-diabetic activity |
CA2512879A1 (en) | 2003-01-17 | 2004-08-12 | Soumya P. Sahoo | N-cyclohexylaminocarbonyl benzenesulfonamide derivatives |
CN101743616B (zh) | 2007-06-28 | 2012-02-22 | 株式会社半导体能源研究所 | 半导体装置的制造方法 |
JP2010531307A (ja) | 2007-06-28 | 2010-09-24 | メルク フロスト カナダ リミテツド | Gpr105活性のアンタゴニストとしての置換縮合ピリミジン |
EP2178537A4 (en) | 2007-07-19 | 2011-08-17 | Merck Sharp & Dohme | BETA-CARBOLIN DERIVATIVES AS ANTIDIBLE COMPOUNDS |
WO2009032249A1 (en) | 2007-09-06 | 2009-03-12 | Merck & Co., Inc. | Soluble guanylate cyclase activators |
US20110301079A1 (en) | 2007-09-21 | 2011-12-08 | Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Neuromedin u receptor agonists and uses thereof |
AU2009322836B2 (en) | 2008-11-25 | 2013-04-04 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
MX2011008952A (es) | 2009-02-26 | 2011-09-27 | Merck Sharp & Dohme | Activadores de guanilato ciclasa solubles. |
DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
NZ603884A (en) * | 2010-05-27 | 2014-06-27 | Merck Sharp & Dohme | Soluble guanylate cyclase activators |
EA201390060A1 (ru) | 2010-07-09 | 2013-07-30 | Байер Интеллектуэль Проперти Гмбх | Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний |
US8895583B2 (en) | 2010-10-28 | 2014-11-25 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
CN103619845B (zh) | 2011-04-21 | 2016-08-17 | 拜耳知识产权有限责任公司 | 氟烷基取代的吡唑并吡啶及其用途 |
CA2834901A1 (en) | 2011-05-06 | 2012-11-15 | Bayer Intellectual Property Gmbh | Substituted imidazopyridines and imidazopyridazines and the use thereof |
ES2648810T3 (es) | 2011-07-06 | 2018-01-08 | Bayer Intellectual Property Gmbh | Pirazolopiridinas sustituidas con heteroarilo y uso de las mismas como estimuladores de la guanilato ciclasa soluble |
AU2012300844B2 (en) | 2011-09-02 | 2017-03-30 | Bayer Intellectual Property Gmbh | Substituted annellated pyrimidine and the use thereof |
DE102012200352A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung |
DE102012200349A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung |
AP2016008970A0 (en) | 2013-07-10 | 2016-01-31 | Bayer Pharma AG | Benzyl-1h-pyrazolo[3,4-b]pyridines and use thereof |
US9611278B2 (en) | 2013-12-11 | 2017-04-04 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
EP3079700B1 (en) | 2013-12-11 | 2020-11-25 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
US9796733B2 (en) | 2014-06-04 | 2017-10-24 | Merck Sharp & Dohme Corp. | Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators |
EP3194386A2 (en) | 2014-09-17 | 2017-07-26 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
TW201625635A (zh) | 2014-11-21 | 2016-07-16 | 默沙東藥廠 | 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物 |
EP3303342B1 (en) | 2015-05-27 | 2021-03-17 | Merck Sharp & Dohme Corp. | Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
US10213429B2 (en) | 2015-05-28 | 2019-02-26 | Merck Sharp & Dohme Corp. | Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
CN108463224A (zh) | 2015-12-14 | 2018-08-28 | 铁木医药有限公司 | sGC刺激剂用于胃肠功能障碍治疗的应用 |
WO2017107052A1 (en) | 2015-12-22 | 2017-06-29 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase stimulators |
JP7098214B2 (ja) | 2016-02-01 | 2022-07-11 | サイクレリオン・セラピューティクス,インコーポレーテッド | 非アルコール性脂肪性肝炎(NASH)の処置のためのsGC刺激物質の使用 |
-
2015
- 2015-12-22 WO PCT/CN2015/098251 patent/WO2017107052A1/en active Application Filing
-
2016
- 2016-12-20 CA CA3009193A patent/CA3009193C/en active Active
- 2016-12-20 UA UAA201808060A patent/UA122264C2/uk unknown
- 2016-12-20 ME MEP-2020-103A patent/ME03748B/me unknown
- 2016-12-20 PE PE2018001156A patent/PE20181802A1/es unknown
- 2016-12-20 MY MYPI2018001031A patent/MY194021A/en unknown
- 2016-12-20 US US15/384,429 patent/US10030027B2/en active Active
- 2016-12-20 LT LTEP16823455.7T patent/LT3394067T/lt unknown
- 2016-12-20 ES ES16823455T patent/ES2794654T3/es active Active
- 2016-12-20 PL PL16823455T patent/PL3394067T3/pl unknown
- 2016-12-20 DK DK16823455.7T patent/DK3394067T3/da active
- 2016-12-20 TN TNP/2018/000219A patent/TN2018000219A1/en unknown
- 2016-12-20 EA EA201891303A patent/EA036445B1/ru not_active IP Right Cessation
- 2016-12-20 KR KR1020187020705A patent/KR102191312B1/ko active IP Right Grant
- 2016-12-20 CN CN201680075365.8A patent/CN108738320B/zh active Active
- 2016-12-20 CR CR20180330A patent/CR20180330A/es unknown
- 2016-12-20 RS RS20200620A patent/RS60344B1/sr unknown
- 2016-12-20 AR ARP160103930A patent/AR107154A1/es unknown
- 2016-12-20 WO PCT/US2016/067654 patent/WO2017112617A1/en active Application Filing
- 2016-12-20 HU HUE16823455A patent/HUE049941T2/hu unknown
- 2016-12-20 SG SG11201805272XA patent/SG11201805272XA/en unknown
- 2016-12-20 TW TW105142318A patent/TWI724079B/zh active
- 2016-12-20 MX MX2018007728A patent/MX2018007728A/es active IP Right Grant
- 2016-12-20 BR BR112018012579-2A patent/BR112018012579B1/pt active IP Right Grant
- 2016-12-20 PT PT168234557T patent/PT3394067T/pt unknown
- 2016-12-20 SI SI201630769T patent/SI3394067T1/sl unknown
- 2016-12-20 JP JP2018532431A patent/JP6454448B2/ja active Active
- 2016-12-20 EP EP16823455.7A patent/EP3394067B1/en active Active
- 2016-12-20 AU AU2016377364A patent/AU2016377364B2/en active Active
-
2018
- 2018-06-13 IL IL260020A patent/IL260020B/en active IP Right Grant
- 2018-06-13 NI NI201800069A patent/NI201800069A/es unknown
- 2018-06-18 CO CONC2018/0006300A patent/CO2018006300A2/es unknown
- 2018-06-19 SV SV2018005715A patent/SV2018005715A/es unknown
- 2018-06-19 CL CL2018001671A patent/CL2018001671A1/es unknown
- 2018-06-21 MX MX2020011080A patent/MX2020011080A/es unknown
- 2018-06-21 PH PH12018501342A patent/PH12018501342A1/en unknown
- 2018-06-22 DO DO2018000153A patent/DOP2018000153A/es unknown
- 2018-06-27 US US16/019,964 patent/US10428076B2/en active Active
- 2018-07-19 EC ECSENADI201854606A patent/ECSP18054606A/es unknown
- 2018-11-06 HK HK18114149.1A patent/HK1255028A1/zh unknown
-
2020
- 2020-05-28 HR HRP20200857TT patent/HRP20200857T1/hr unknown
- 2020-06-16 CY CY20201100547T patent/CY1123173T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123173T1 (el) | Παραγωγα 4-αμινο-2-(1η-πυραζολο[3,4-β]πυριδιν-3-υλ)-6-οξο-6,7-διϋδρο-5η-πυρρολο[2,3-d]πυριμιδινης και τα αντιστοιχα παραγωγα (1η-ινδαζολ-3-υλιου) ως διαμορφωτες cgmp για αγωγη καρδιαγγειακων παθησεων | |
CY1119487T1 (el) | Αναστολεις κιναζολινης των ενεργοποιητικων μεταλλαγμενων μορφων του υποδοχεα του επιδερμικου αυξητικου παραγοντα | |
CY1122703T1 (el) | 1η-πυραζολο[3,4-β]πυριδινες και θεραπευτικες χρησεις αυτων | |
DK3027624T3 (en) | THIENO [3,2-D] PYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS | |
CY1122601T1 (el) | Αναστολεις gsk3 και μεθοδοι χρησης αυτων | |
CY1116231T1 (el) | ΑΛΑΤΑ ΥΠΟΚΑΤΕΣΤΗΜΕΝΗΣ 2,3-ΔIYΔPOΪMIΔAZO[l,2-C] ΚΙΝΑΖΟΛΙΝΗΣ | |
EA201291348A1 (ru) | Активаторы растворимой гуанилатциклазы | |
EA201391769A1 (ru) | Имидазопиридиновые соединения | |
PE20151084A1 (es) | Derivados de pirimidinona inhibidoras de la elastasa de neutrofilos humanos (hne) | |
CY1122587T1 (el) | 1-[2-(αμινομεθυλο)βενζυλο]-2-θειοξο-1,2,3,5-τετραϋδρο-4η-πυρρολο[3,2-d]πυριμιδιν-4-ονες ως αναστολεις της μυελοϋπεροξειδασης | |
AU2014220717A1 (en) | 2-aminopyrimidine derivatives for the treatment of viral infections | |
US20150284339A1 (en) | Heterocyclic substituted 2-amino quinazoline derivatives for the treatment of viral infections | |
ECSP12011921A (es) | Procedimiento para la preparación de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo y su purificación para su uso como principio activo farmacéutico | |
MX2018004332A (es) | Sales farmaceuticas, formas fisicas y composiciones de inhibidores de pirrolopirimidina cinasa, y metodos para fabricar las mismas. | |
MX2019006165A (es) | Proceso para la preparacion de derivados del acido biliar de las sulfonilureas. | |
SG136123A1 (en) | Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | |
JP2016540803A5 (el) | ||
CO2022002567A2 (es) | Proteínas de fusión terapéuticas | |
AR089860A1 (es) | Analogos de la grelina | |
EA201791276A1 (ru) | Замещенные пиперидином трициклические производные пиразоло[1,5-a]пиримидина с ингибирующей активностью в отношении репликации респираторно-синцитиального вируса (rsv) | |
CY1124442T1 (el) | ΑΛΑΣ ΑΜΙΝΗΣ TOY (lR,3S)-3-(5-KYANO-4-ΦAINYΛ-l,3- ΘEIAZOΛ-2-ΥΛΚΑΡΒΑΜΟΫΛ) ΚΥΚΛΟΠΕΝΤΑΝΙΟ ΚΑΡΒΟΞΥΛΙΚΟΥ ΟΞΕΟΣ | |
ES2879821T3 (es) | Compuestos de 5-(pirimidin-4-il)-2-(pirrolidin-1-il)nicotinonitrilo como inhibidores de las cinasas IKKe, TBK1 y/o SIK2 | |
NZ704727A (en) | Tris(hetero)arylpyrazoles and use thereof | |
Benkirane et al. | Synthetic Routes and Pharmacological Activities of Purine Derivatives: A Review | |
Ding | Selective DDRs inhibitors as novel therapeutic agents for human cancers and pulmonary fibrosis |